A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases

Author(s): Rubén Casado-Arroyo, Angel Lanas, Pedro Brugada

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 35 , 2015

Become EABM
Become Reviewer


This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings. Aspirin reduces one fourth of all major cardiovascular events but also increases major gastrointestinal bleeds by about half. As with other cardiovascular prevention strategies, the absolute benefit of aspirin is linearly related to the cardiovascular risk of the patient. The risk-benefit of aspirin can vary substantially in different settings: in secondary prevention, the benefits usually outweigh the excess of major bleeding complications. In primary prevention, it is not unusual that the number of vascular events avoided equals the number of major bleeds induced by aspirin. Finally, there is a growing body of evidence suggesting that aspirin may interfere with the early stages of cancer, metastasis and mortality. For all these reasons, in this article new developments in the field directed towards individualized risk assessment strategies are also discussed.

Keywords: Aspirin, prevention cardiovascular diseases, GI damage, proton pump inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [5101 - 5107]
Pages: 7
DOI: 10.2174/1381612821666150915110322
Price: $65

Article Metrics

PDF: 40